MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Corcept Therapeutics Incorporated DPO Ratio 2011-2025 | CORT
Annual DPO Ratio Corcept Therapeutics Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 550 | 827 | 640 | 603 | 591 | 500 | 579 | 881 | 406 | 355 | 780 | 6.08 K | 15.3 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.3 K | 355 | 2.16 K |
Quarterly DPO Ratio Corcept Therapeutics Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 575 | 684 | 883 | 606 | 579 | 527 | 685 | 556 | 369 | - | 279 | 321 | 590 | - | 564 | 534 | 631 | - | 792 | 780 | 440 | - | 474 | 499 | 581 | - | 577 | 654 | 655 | - | 802 | 1.01 K | - | - | - | - | - | - | 472 | 275 | 485 | - | 732 | 800 | 1.12 K | - | 5.43 K | 9.45 K | 14.1 K | - | 14.5 K | 7.23 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.5 K | 275 | 1.9 K |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
23 | $ 4.93 | 4.78 % | $ 818 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
887 | $ 3.2 | -1.69 % | $ 247 M |  USA |
 |
Aptevo Therapeutics
APVO
|
239 | $ 1.07 | -5.75 % | $ 295 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M | Canada |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
28.5 | $ 26.45 | 4.67 % | $ 1.28 B | USA |
 |
Anika Therapeutics
ANIK
|
54.4 | $ 9.6 | 0.37 % | $ 141 M | USA |
 |
Catalyst Biosciences
CBIO
|
18.8 | $ 12.98 | -7.91 % | $ 854 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
142 | - | -6.81 % | $ 3.04 B | USA |
 |
Axon Enterprise
AXON
|
29.9 | $ 548.58 | -2.78 % | $ 41.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
186 | $ 2.37 | 2.83 % | $ 14.9 M | USA |
 |
AstraZeneca PLC
AZN
|
265 | $ 91.59 | 1.95 % | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
6.17 K | $ 27.09 | -1.53 % | $ 1.74 M | USA |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
105 | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
199 | $ 11.33 | -1.78 % | $ 733 M | USA |
 |
Biogen
BIIB
|
65.4 | $ 175.2 | 0.63 % | $ 25.5 B | USA |
 |
Abeona Therapeutics
ABEO
|
2.52 K | $ 5.07 | -5.5 % | $ 108 M | USA |
 |
ADiTx Therapeutics
ADTX
|
5.15 K | $ 1.43 | -36.18 % | $ 18.8 K | USA |
 |
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | USA |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
83.2 | $ 24.29 | 2.84 % | $ 2.88 B | USA |